Safety and Pharmacokinetic Profile of CKD-581

Summary

This study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-581 injection in patients with Lymphoma failed to standard therapy. The usefulness of the this regimen is evaluated by response rate, progression free survival.

Timeline

Start

2012-05

Primary completion

2016-03

Completion

2016-06

Drugs

Indications